CDK4 and melanoma: For instance, cellular senescence induced by CDK4/6-targeted drugs in melanoma was shown to repress a resistance program expressed by malignant cells prior to immunotherapy, which is associated with T cell exclusion and predicts unfavorable clinical response to anti-PD-1 therapy [46].